AstraZeneca Results Presentation Deck

Total Revenue ($m) 2,500 Rare Disease - H1 and Q2 2023 Continued expansion in neurology, growth beyond complement 2,000 1,500 1,000 500 0 Q3 2 2021 Q4 Rare Disease H1 2023 $3.8bn, +12% Q1 Q2 2022 Q3 Ultomiris Soliris Strensiq Others¹ Q4 Q1 2023 CEO Opening Remarks Q2 Financial Results Oncology BioPharmaceuticals Rare Disease Q2 2023: key dynamics CEO Closing Remarks Continued strength of C5 Franchise Ultomiris +66%, driven by growth in neurology, expansion into new markets and successful conversion from Soliris All growth rates at CER. 1. Includes Kanuma and Koselugo. 2. Q3 2021 Total Revenues reported only comprise of those booked by AstraZeneca following completion of the acquisition of Alexion on 21 July 2021. 25 C5 C5 inhibitors Ultomiris and Soliris; CER = constant exchange rates; NMOSD = neuromyelitis optica spectrum disorder. Collaboration partners: Merck & Co., Inc. (Koselugo). Soliris (19%), decline reflecting conversion partially offset by NMOSD growth Strensiq, +25% and Koselugo, +30% Reflecting continued strength of patient demand and expansion into new markets

View entire presentation